Delivery Order 75N93019D00016-75N93022F00001

Award Date 8/29/22
Potential Completion Date 8/28/23
Potential Value $616K
Ultimate Awardee
Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Birmingham, AL 35294, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to the University of Alabama at Birmingham (UAB) for a Comprehensive Viral Screening Panel to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses. The contract is a Delivery Order under the "In Vitro Assessments of Antimicrobial Activity (IVAAA)"...
The Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a $499,760.00 firm fixed-price delivery order contract to the University of Alabama at Birmingham (UAB) for in vitro assessments of antimicrobial activity. This contract is under the parent "In Vitro Assessments of Antimicrobial Activity (IVAAA)" Indefinite Delivery Contract (IDC). UAB, a non-profit, state-controlled institution of higher...
This is a firm fixed-price delivery order awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to the University of Alabama at Birmingham (UAB) on August 22, 2017. The contract has a potential value of $845,508.52 and a completion date of September 15, 2018. The contract is for in vitro assessment for antimicrobial activity and a comprehensive viral screening panel. This delivery order is...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, has awarded a Delivery Order contract to the University of Alabama at Birmingham (UAB) to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses. The contract is a Firm Fixed Price type awarded under the larger In Vitro Assessments of Antimicrobial Activity (IVAAA) Indefinite Delivery Contract (IDC). The contract has a ceiling value of $548,829.16 and a...
This contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH), to the University of Alabama at Birmingham (UAB) as a Delivery Order. The contract is for "IN VITRO ASSESSMENTS FOR ANTIMICROBIAL ACTIVITY" and is part of the larger "In Vitro Antimicrobial Assessments 2011-2018" Indefinite Delivery, Indefinite Quantity (IDIQ) contract. The contract has a ceiling value of $1,277,140.50 and a...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a Firm Fixed Price Delivery Order to the University of Alabama at Birmingham (UAB), doing business as U A B, for a "COMPREHENSIVE PANEL FOR VIRUSES" contract with a ceiling value of $1,053,577.42. The contract is under the broader In Vitro Antimicrobial Assessments 2011-2018 Indefinite Delivery Contract (IDC) and has a completion date of September 29, 2016. UAB is a non-profit, public research university...
This is a firm fixed-price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to the University of Alabama at Birmingham (UAB) under the In Vitro Antimicrobial Assessments 2011-2018 IDIQ contract. The contract, which does not have a set-aside designation, is for $216,637.50 and covers in vitro antimicrobial assessments under Task B07. UAB, a leading public research university and academic medical center,...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to the University of Alabama at Birmingham (UAB) to provide in vitro assessments for antimicrobial activity. The contract, valued at $12,178, is a delivery order under the larger "In Vitro Antimicrobial Assessments 2011-2018" Indefinite Delivery Contract (IDC) vehicle. The award has a completion date of November 14, 2013,...
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) awarded a $978,590.76 Firm Fixed Price Delivery Order to the University of Alabama at Birmingham (UAB) on August 15, 2014 for a "Comprehensive Panel for Viruses" requirement. This Delivery Order was placed under NIAID's In Vitro Antimicrobial Assessments 2011-2018 Indefinite Delivery, Indefinite Quantity (IDIQ) contract and had a completion date of September 29, 2015. UAB, a public research university and academic...
This federal contract award was made by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to the University of Alabama at Birmingham (UAB) to provide a "SUPPLEMENT TO COMPREHENSIVE PANEL FOR VIRUSES". The $26,500.00 Firm Fixed Price contract was awarded on March 24, 2015 as a Delivery Order under the "In Vitro Antimicrobial Assessments 2011-2018" Indefinite Delivery Contract (IDC). The contract has no set-aside designation. As a leading...

This contract was awarded by the Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases to the University of Alabama at Birmingham (UAB), an internationally renowned research university and academic medical center. The contract, valued at $616,373.16, is a Firm Fixed Price Delivery Order under the "In Vitro Assessments of Antimicrobial Activity (IVAAA)" master IDIQ contract. The objective is to determine the antiviral inhibitory effect and cytotoxicity of experimental antiviral compounds against viruses listed in the Statement of Work, as well as other rapidly emerging viruses using the same assay methodology. This contract does not have a set-aside designation and is expected to be completed by August 28, 2023. UAB has an extensive track record of delivering biomedical and public health research under federal grants and contracts, leveraging its expertise in areas such as cancer, infectious diseases, chronic illnesses, neuroscience, and health disparities.

Generated 5/17/24, 9:40 AM